search
Back to results

Colchicine as Treatment for People With Hand Osteoarthritis (COLOR)

Primary Purpose

Osteoarthritis Hand, Osteoarthritis Finger

Status
Completed
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Colchicine 0.5 MG
Placebo
Sponsored by
Henning Bliddal
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis Hand

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ≥18 years.
  2. Hand OA according to the ACR criteria above.
  3. Hand OA finger pain: Pain at rest ≥40 mm on VAS (0 to 100 mm range).

Exclusion Criteria:

Comorbidities

  1. Other known medical disease that may affect joints, e.g. RA, gout, PsA
  2. Positive anti-cyclic citrullinated peptide (>10 kU/L)
  3. Known cutaneous deposition diseases (e.g. amyloidosis or porphyria).
  4. Known blood dyscrasias and coagulation disorders
  5. Known malignancy (except successfully treated squamous or basal cell skin carcinoma)
  6. Elevated alanine transaminase (>45 U/L females, >70 U/L for males)
  7. Creatinine clearance ≤60 ml/min
  8. Elevated creatine kinase (>210 U/L females, >280 U/L for males)
  9. Known allergies towards the interventions
  10. Drug or alcohol abuse in the last year
  11. Generalised pain syndromes such as fibromyalgia
  12. Current reflux
  13. Current or recurrent diarrhoeal illnesses
  14. Current abdominal pain
  15. Known peripheral neuropathies
  16. Any other condition or impairment that, in the opinion of the investigator, makes a potential participant unsuitable for participation or which obstruct participation, such as e.g. psychiatric disorders.

    Medical history

  17. History of hand surgery within 12 months prior enrolment.
  18. History of arthroplasty or arthrodesis in the hand Management strategies
  19. Treatment with P-glycoprotein inhibitors and/or cytochrome P450 3A4 (CYP3A4) inhibitors, see section "Colchicine safety in drug-drug interactions" and table 7. If potential participants have been treated with these pharmaceuticals previously, treatment must be terminated 5 half-lifes before initiation of study drug.
  20. Use of systemic corticosteroids equivalent of ≥ 7.5 mg prednisolone daily within 3 months.
  21. Participation in experimental device or experimental drug study 3 months prior to enrolment.
  22. Intra-articular treatments or aspirations of any kind of any joint in the hands 3 months before inclusion
  23. Intra-articular corticosteroids into any joint 1 months before inclusion
  24. Current use of synthetic or non-synthetic opioids
  25. Scheduled surgery during study participation
  26. Planning to start other treatment for hand OA in the study participation period.

    Reproductive system

  27. Pregnancy.
  28. Planned pregnancy within the study period, 3 months after end of study treatment for female fertile participant and 6 months after end of study treatment for male participant.
  29. Insufficient anti-conception therapy for female fertile participants within the study period and 3 months after end of study treatment. Sufficient anti-conception therapy consists of intra-uterine device (coil),hormonal anti-conception (birth control pills, implant, intra-uterine system, dermal patch, vaginal ring, or injections) or sexual abstinence Female participants are considered infertile if they are postmenopausal or if they have undergone surgical sterilisation (bilateral salpingectomy, hysterectomy or bilateral oophorectomy). Postmenopausal state is defined as no menses for 12 months without alternative medical cause before inclusion in the study. Menopause state will be confirmed by measurement of follicle stimulating hormone.
  30. Insufficient anti-conception therapy for male participants within the study period and 6 months after end of study treatment. Sufficient anti-conception therapy consists of condom or sexual abstinence. Male participants are considered sterile if they have undergone surgical sterilisation (vasectomy).
  31. Breast-feeding

A target hand will be selected for outcome assessment once individual fulfills in- and exclusions criterias. Selection of the target hand will adhere to the following, with advancement to next step if unable to choose target hand based on the given criteria.

  1. The hand with most overall pain, assessed by VAS finger joint pain.
  2. The hand with most overall reduced function, assessed by AUSCAN function subscale.
  3. The hand with most overall stiffness, assessed by AUSCAN stiffness subscale.
  4. The hand with most swollen joints, assessed by physician joint count.
  5. The hand with most tender joints, assessed by physician joint count.
  6. The hand with highest summed radiographic score, assessed by radiographic scoring of conventional X-ray.
  7. If unable to select target hand based on the above criteria, a target hand will be randomly assigned.

Sites / Locations

  • The Parker Institute, Bispebjerg and Frederiksberg Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Colchicine

Placebo

Arm Description

Tablet colchicine 0.5 mg administered two times daily

Tablet placebo administered two times daily

Outcomes

Primary Outcome Measures

Finger pain
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, on changes in finger joint pain of the target hand from baseline to week 12, in patients with painful hand OA measured on a visual analogue scale spanning from 0 to 100, where 0 equals no symptoms and 100 equals worst imaginable symptoms.

Secondary Outcome Measures

Function
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in function of both hands measured on the Australian/Canadian Hand Index Function Score spanning from 0 to 900, where higher scores equals worse function.
Thumb base pain
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in thumb base pain of the target hand measured on a visual analogue scale spanning from 0 to 100, where 0 equals no symptoms and 100 equals worst imaginable symptoms.
Pain hands
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in pain of both hands measured on the Australian/Canadian Hand Index Pain Score spanning from 0 to 500, where higher scores equals worse pain.
Joint activity
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in joint activity of the target hand measured on physician tender joint count
Patient global assessment
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in patient global assessment measured on a visual analogue scale spanning from 0 to 100, where 0 equals no symptoms and 100 equals worst imaginable symptoms.
Quality of life measured by European Quality of Life 5 Dimensions
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in quality of life measured on the European Quality of Life 5 Dimensions spanning from -0.624 to 1.000, where higher scores equals better quality of life.
Hand strength
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in hand strength of the target hand measured on grippit
Number of treatment responders according to OMERACT-OARSI response criteria
The following two conditions is observed at the post-baseline assessment: In either pain (finger pain) or function (function), a high improvement in the subscale, where high improvement in a subscale is achieved if there is both a > 50% improvement from Baseline and an absolute change from Baseline of > 20 percent points (0-100 scale), OR Improvement in at least two of the following three: Improvement in pain (finger pain) defined as > 20% improvement from Baseline and an absolute change from Baseline of > 10 points (0-100 scale) Improvement in function (function) defined as > 20% improvement from Baseline and an absolute change from Baseline of > 10 points (0-100 scale) Improvement in patient's global assessment defined as > 20% improvement from Baseline and an absolute change from Baseline of > 10 mm (0-100 scale)

Full Information

First Posted
October 12, 2020
Last Updated
February 14, 2023
Sponsor
Henning Bliddal
search

1. Study Identification

Unique Protocol Identification Number
NCT04601883
Brief Title
Colchicine as Treatment for People With Hand Osteoarthritis
Acronym
COLOR
Official Title
Colchicine Treatment for Patients With Hand Osteoarthritis: A Randomised, Placebo-controlled Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
January 15, 2021 (Actual)
Primary Completion Date
August 3, 2022 (Actual)
Study Completion Date
August 3, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Henning Bliddal

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study aims to compare oral colchicine 0.5 mg administered two times daily for 12 weeks with placebo as a treatment of hand OA symptoms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis Hand, Osteoarthritis Finger

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Colchicine
Arm Type
Experimental
Arm Description
Tablet colchicine 0.5 mg administered two times daily
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Tablet placebo administered two times daily
Intervention Type
Drug
Intervention Name(s)
Colchicine 0.5 MG
Intervention Description
The intervention tablets are commercially available Colchicine "Tiofarma"
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Encapsulated placebo tablets. Placebo is identical to the active intervention.
Primary Outcome Measure Information:
Title
Finger pain
Description
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, on changes in finger joint pain of the target hand from baseline to week 12, in patients with painful hand OA measured on a visual analogue scale spanning from 0 to 100, where 0 equals no symptoms and 100 equals worst imaginable symptoms.
Time Frame
Week 12
Secondary Outcome Measure Information:
Title
Function
Description
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in function of both hands measured on the Australian/Canadian Hand Index Function Score spanning from 0 to 900, where higher scores equals worse function.
Time Frame
Week 12
Title
Thumb base pain
Description
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in thumb base pain of the target hand measured on a visual analogue scale spanning from 0 to 100, where 0 equals no symptoms and 100 equals worst imaginable symptoms.
Time Frame
Week 12
Title
Pain hands
Description
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in pain of both hands measured on the Australian/Canadian Hand Index Pain Score spanning from 0 to 500, where higher scores equals worse pain.
Time Frame
Week 12
Title
Joint activity
Description
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in joint activity of the target hand measured on physician tender joint count
Time Frame
Week 12
Title
Patient global assessment
Description
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in patient global assessment measured on a visual analogue scale spanning from 0 to 100, where 0 equals no symptoms and 100 equals worst imaginable symptoms.
Time Frame
Week 12
Title
Quality of life measured by European Quality of Life 5 Dimensions
Description
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in quality of life measured on the European Quality of Life 5 Dimensions spanning from -0.624 to 1.000, where higher scores equals better quality of life.
Time Frame
Week 12
Title
Hand strength
Description
To compare the effect of oral colchicine 0.5 mg bid, relative to placebo, from baseline to week 12, in patients with painful hand OA on changes in hand strength of the target hand measured on grippit
Time Frame
Week 12
Title
Number of treatment responders according to OMERACT-OARSI response criteria
Description
The following two conditions is observed at the post-baseline assessment: In either pain (finger pain) or function (function), a high improvement in the subscale, where high improvement in a subscale is achieved if there is both a > 50% improvement from Baseline and an absolute change from Baseline of > 20 percent points (0-100 scale), OR Improvement in at least two of the following three: Improvement in pain (finger pain) defined as > 20% improvement from Baseline and an absolute change from Baseline of > 10 points (0-100 scale) Improvement in function (function) defined as > 20% improvement from Baseline and an absolute change from Baseline of > 10 points (0-100 scale) Improvement in patient's global assessment defined as > 20% improvement from Baseline and an absolute change from Baseline of > 10 mm (0-100 scale)
Time Frame
Week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥18 years. Hand OA according to the ACR criteria above. Hand OA finger pain: Pain at rest ≥40 mm on VAS (0 to 100 mm range). Exclusion Criteria: Comorbidities Other known medical disease that may affect joints, e.g. RA, gout, PsA Positive anti-cyclic citrullinated peptide (>10 kU/L) Known cutaneous deposition diseases (e.g. amyloidosis or porphyria). Known blood dyscrasias and coagulation disorders Known malignancy (except successfully treated squamous or basal cell skin carcinoma) Elevated alanine transaminase (>45 U/L females, >70 U/L for males) Creatinine clearance ≤60 ml/min Elevated creatine kinase (>210 U/L females, >280 U/L for males) Known allergies towards the interventions Drug or alcohol abuse in the last year Generalised pain syndromes such as fibromyalgia Current reflux Current or recurrent diarrhoeal illnesses Current abdominal pain Known peripheral neuropathies Any other condition or impairment that, in the opinion of the investigator, makes a potential participant unsuitable for participation or which obstruct participation, such as e.g. psychiatric disorders. Medical history History of hand surgery within 12 months prior enrolment. History of arthroplasty or arthrodesis in the hand Management strategies Treatment with P-glycoprotein inhibitors and/or cytochrome P450 3A4 (CYP3A4) inhibitors, see section "Colchicine safety in drug-drug interactions" and table 7. If potential participants have been treated with these pharmaceuticals previously, treatment must be terminated 5 half-lifes before initiation of study drug. Use of systemic corticosteroids equivalent of ≥ 7.5 mg prednisolone daily within 3 months. Participation in experimental device or experimental drug study 3 months prior to enrolment. Intra-articular treatments or aspirations of any kind of any joint in the hands 3 months before inclusion Intra-articular corticosteroids into any joint 1 months before inclusion Current use of synthetic or non-synthetic opioids Scheduled surgery during study participation Planning to start other treatment for hand OA in the study participation period. Reproductive system Pregnancy. Planned pregnancy within the study period, 3 months after end of study treatment for female fertile participant and 6 months after end of study treatment for male participant. Insufficient anti-conception therapy for female fertile participants within the study period and 3 months after end of study treatment. Sufficient anti-conception therapy consists of intra-uterine device (coil),hormonal anti-conception (birth control pills, implant, intra-uterine system, dermal patch, vaginal ring, or injections) or sexual abstinence Female participants are considered infertile if they are postmenopausal or if they have undergone surgical sterilisation (bilateral salpingectomy, hysterectomy or bilateral oophorectomy). Postmenopausal state is defined as no menses for 12 months without alternative medical cause before inclusion in the study. Menopause state will be confirmed by measurement of follicle stimulating hormone. Insufficient anti-conception therapy for male participants within the study period and 6 months after end of study treatment. Sufficient anti-conception therapy consists of condom or sexual abstinence. Male participants are considered sterile if they have undergone surgical sterilisation (vasectomy). Breast-feeding A target hand will be selected for outcome assessment once individual fulfills in- and exclusions criterias. Selection of the target hand will adhere to the following, with advancement to next step if unable to choose target hand based on the given criteria. The hand with most overall pain, assessed by VAS finger joint pain. The hand with most overall reduced function, assessed by AUSCAN function subscale. The hand with most overall stiffness, assessed by AUSCAN stiffness subscale. The hand with most swollen joints, assessed by physician joint count. The hand with most tender joints, assessed by physician joint count. The hand with highest summed radiographic score, assessed by radiographic scoring of conventional X-ray. If unable to select target hand based on the above criteria, a target hand will be randomly assigned.
Facility Information:
Facility Name
The Parker Institute, Bispebjerg and Frederiksberg Hospital
City
Copenhagen
State/Province
DK
ZIP/Postal Code
2500
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Colchicine as Treatment for People With Hand Osteoarthritis

We'll reach out to this number within 24 hrs